EMERALD: elacestrant vs physicians choice in ER+/HER2- breast cancer VJOncology 1:27 2 years ago 734 Скачать Далее
EMERALD: elacestrant vs. SOC for patients with ER+ HER2- metastatic breast cancer VJOncology 2:03 2 years ago 1 626 Скачать Далее
Update of EMERALD by duration of CDK4/6i in metastatic setting: elacestrant v SoC in ER+/HER2- mBC VJOncology 0:46 1 year ago 276 Скачать Далее
SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC ecancer 4:39 2 years ago 377 Скачать Далее
What EMERALD Phase III trial could mean for breast cancer patients | Virginia Kaklamani, MD UT Health San Antonio MD Anderson Cancer Center 1:01 1 year ago 392 Скачать Далее
Elacestrant shows improved PFS in patients with ER-positive/HER2-negative metastatic breast cancer ecancer 3:24 1 year ago 345 Скачать Далее
Elacestrant significantly prolongs PFS for ER+/HER2- metastatic BC without prior chemotherapy pts ecancer 2:06 2 years ago 678 Скачать Далее
The impact of the EMERALD trial results based on duration of prior CDK4/6i in the metastatic setting VJOncology 0:30 1 year ago 115 Скачать Далее
Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancer European Society for Medical Oncology (ESMO) 4:50 1 year ago 1 332 Скачать Далее
GS2-02: "Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s..." San Antonio Breast Cancer Symposium 20:37 1 year ago 560 Скачать Далее
Assessing elacestrant in ctDNA-positive patients with ER+ breast cancer VJOncology 3:01 2 years ago 207 Скачать Далее
EMERALD lead to the Elacestrant FDA Approval - OncBrothers in discussion w/ Dr. Virginia Kaklamani OncBrothers: Practice-Changing Cancer Discussions 17:11 1 year ago 500 Скачать Далее
Key trial updates in SERDs in ER+/HER2- breast cancer from SABCs 2022 VJOncology 1:17 1 year ago 149 Скачать Далее
What does the future hold for SERDs in ER+ breast cancer? VJOncology 2:35 1 year ago 387 Скачать Далее
EMERALD Study lead to the Elacestrant FDA Approval - OncBrothers in discussion w/ Dr. Aditya Bardia OncBrothers: Practice-Changing Cancer Discussions 16:10 1 year ago 856 Скачать Далее
FDA approves Elacestrant (Orserdu) for ER-positive, HER2-negative, ESR1-mutated breast cancer medXclusive Learning 0:50 1 year ago 870 Скачать Далее
Navigating the Expanding Treatment Arsenal for ER+/HER2- Breast Cancer PeerView Oncology 57:18 2 years ago 2 604 Скачать Далее
Updated results by duration of prior CDK4/6i in the met setting of the Phase III EMERALD trial VJOncology 2:21 1 year ago 130 Скачать Далее
ELAINE 1: LAS vs fulv in la ER+/HER2- mBC ESR1m + disease progression on AI and CDK4/6i inhibitors VJOncology 5:47 1 year ago 120 Скачать Далее
